GlassScriptPhysician profile
Swetha Panati
NPI 1992934228
$7,054.74
in general payments reported to CMS, 2019-2025
55 companies · $230 in 2025
The $230 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,138 · 2020: $387 · 2021: $120 · 2022: $3,242 · 2023: $752 · 2024: $185 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.50 |
| Education | $187.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $654.26 | 2019-2024 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $642.24 | 2019-2025 | |
| Amgen INC. | $517.84 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $495.01 | 2019-2022 | |
| Seagen INC. | $399.60 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Astrazeneca Pharmaceuticals LP | $393.74 | 2019-2025 | Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $358.30 | 2019-2025 | Darzalex, Talvey |
| Genzyme Corporation | $350.89 | 2019-2023 | |
| Pfizer INC. | $339.38 | 2019-2025 | |
| Exelixis INC. | $229.33 | 2019-2024 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $174.55 | 2022-2025 | Fotivda |
| Genentech USA, INC. | $167.75 | 2019-2022 | |
| Celgene Corporation | $151.73 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.44 | 2019-2022 | |
| Lilly USA, LLC | $128.87 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Panati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.